Pharmaceutical Chemistry Books for GATE exam

The Union budget 2008 adding flavours to the Indian pharmaceutical industry seem ambiguous in some dimensions. As we discussed earlier, weighted deduction of 125% on payments made for outsourcing research services is a positive factor for R&D focused companies such as Ranbaxy and Nicholas Piramal. But we know that a lion’s shares of the Indian pharmaceutical industries are lacking the facilities of research and development. Due to the practice of the process patents for the last few decades, these companies were mainly focusing on reverse engineering and in the production of generic version of the drugs. So the weighted deduction will not be helpful to these companies for whom the research and development activities are still a ‘mirage’.